GlassScriptPhysician profile
Juan Villazon
NPI 1174515605
$1,387.07
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $550 · 2021: $318 · 2022: $197 · 2023: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $128.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $231.42 | 2020-2021 | |
| Amgen INC. | $231.15 | 2019-2022 | |
| Biogen, INC. | $210.53 | 2019-2023 | Tysabri, Vumerity |
| Supernus Pharmaceuticals, INC. | $131.96 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $117.09 | 2020-2021 | |
| Sk Life Science, INC. | $71.66 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $61.83 | 2020 | |
| Lilly USA, LLC | $57.84 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $47.46 | 2020 | |
| Neurelis, INC. | $35.20 | 2020 | |
| Celgene Corporation | $33.58 | 2020-2021 | |
| Ucb, INC. | $29.13 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $29.13 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $24.65 | 2021 | |
| Eisai INC. | $23.33 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $21.77 | 2023 | Vyvgart Hytrulo |
| Genzyme Corporation | $17.34 | 2020 | |
| Emd Serono, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Villazon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.